Ismail Elshahat Ibrahem, Morgan Ashraf Elsayed, Farag Raghda Elsayed
Audiology Unit - ENT Department, Faculty of Medicine, Mansoura University, Egypt.
Department of Tropical Medicine, Faculty of Medicine, Mansoura University, Egypt.
J Otol. 2018 Mar;13(1):10-15. doi: 10.1016/j.joto.2017.11.001. Epub 2017 Dec 19.
Evaluating the auditory function in patients with chronic hepatitis C treated with sofosbuvir and ribavirin.
This study involved 80 patients with chronic hepatitis C who agreed to receive sofosbuvir and ribavirin. All participants were subjected to baseline otological and audiological assessment just before treatment. The audiological assessment included standard pure tone audiometry, extended high-frequency audiometry, immitancemetry and otoacoustic emissions (OAEs) (transient and distortion product). According to baseline hearing threshold measurements, the study population was divided into 2 groups. Group 1 included 42 patients with normal hearing sensitivity (250-8000 Hz), and Group 2 included 38 patients with sensorineural hearing loss. After 24 weeks of therapy, otological and audiological assessments were repeated and compared between the two groups and before and after therapy.
Post-treatment hearing threshold evaluation showed no significant difference from pretreatment evaluation at all tested frequencies. There was no statistically significant difference between pre and post-treatment otoacoustic emissions results.
Therapy with sofosbuvir and ribavirin in chronic hepatitis C has no noticeable effects on cochlear functions.
评估接受索磷布韦和利巴韦林治疗的慢性丙型肝炎患者的听觉功能。
本研究纳入了80例同意接受索磷布韦和利巴韦林治疗的慢性丙型肝炎患者。所有参与者在治疗前均接受了基线耳科和听力学评估。听力学评估包括标准纯音听力测定、扩展高频听力测定、声导抗测量和耳声发射（瞬态和畸变产物）。根据基线听力阈值测量结果，将研究人群分为2组。第1组包括42例听力敏感度正常（250 - 8000赫兹）的患者，第2组包括38例感音神经性听力损失患者。治疗24周后，重复进行耳科和听力学评估，并在两组之间以及治疗前后进行比较。
治疗后听力阈值评估显示，在所有测试频率下与治疗前评估相比无显著差异。治疗前后耳声发射结果无统计学显著差异。
索磷布韦和利巴韦林治疗慢性丙型肝炎对耳蜗功能无明显影响。
